Comphya closes CHF 7.5M Series A to advance erectile dysfunction therapy
09.07.2025
Swiss medtech startup Comphya has completed an oversubscribed Series A round, bringing total equity funding to CHF 7.5M. The funds will accelerate clinical development of its implantable neurostimulation therapy for erectile dysfunction.
 |
 |
Lausanne-based Medtech startup Comphya, is developing CaverSTIM, the first implantable neuromodulator designed to restore erectile function in patients unresponsive to medication—particularly those recovering from prostate surgery. The newly closed Series A round, including convertible loan conversions, adds to the CHF 4.35M secured earlier this year.
The funding supports the ongoing clinical trial in Australia, where patients implanted with CaverSTIM during prostatectomy procedures have shown promising safety and efficacy results. Data presented at the 2025 American Urological Association Annual Meeting indicated preserved erectile function in most participants without the need for additional therapies and no adverse events reported.
The additional capital will allow Comphya to expand recruitment in Australia and initiate a U.S. pilot study, launched at Johns Hopkins following FDA IDE approval. These efforts will lay the groundwork for a pivotal U.S. trial slated for 2026, with a Series B round planned to finance its execution.
The close of the round aligns with leadership changes at Comphya, including the appointment of Pim van Wesel as CEO in May 2025 to steer the company’s clinical and strategic development.
Comphya has won Venture Kick, participated in Venture Leaders Life Sciences, and beem ranked among the TOP 100 Swiss Startups.
Comphya's team
The funding supports the ongoing clinical trial in Australia, where patients implanted with CaverSTIM during prostatectomy procedures have shown promising safety and efficacy results. Data presented at the 2025 American Urological Association Annual Meeting indicated preserved erectile function in most participants without the need for additional therapies and no adverse events reported.
The additional capital will allow Comphya to expand recruitment in Australia and initiate a U.S. pilot study, launched at Johns Hopkins following FDA IDE approval. These efforts will lay the groundwork for a pivotal U.S. trial slated for 2026, with a Series B round planned to finance its execution.
The close of the round aligns with leadership changes at Comphya, including the appointment of Pim van Wesel as CEO in May 2025 to steer the company’s clinical and strategic development.
Comphya has won Venture Kick, participated in Venture Leaders Life Sciences, and beem ranked among the TOP 100 Swiss Startups.
Comphya's team